2 months Wells Fargo & Company Cuts Editas Medicine (NASDAQ:EDIT) Price Target to $9.00 MarketBeat
Wells Fargo & Company decreased their price target on Editas Medicine from $27.00 to $9.00 and set an “overweight” rating for the company in a research report on Wednesday.
Nasdaq 100 · Science · Wells Fargo&Co (WFC)
X